Seagen Combo Has 100% Progression Free Survival at 12 months in Phase 2 Trial in Early Hodgkin Lymphoma

 – 88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months –

– Investigational regimen that eliminates two commonly used chemotherapy agents, vinblastine and bleomycin, continues to show consistent safety and tolerability profile, with no cases of febrile neutropenia and no new safety signals observed –

https://www.businesswire.com/news/home/20231210494461/en/